Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease

    Research output: Contribution to journalArticleScientificpeer-review

    Original languageEnglish
    JournalActa Paediatrica
    Volume96
    Pages (from-to)128-134
    Number of pages7
    ISSN0803-5253
    DOIs
    Publication statusPublished - 2007
    MoE publication typeA1 Journal article-refereed

    Fields of Science

    • 312 Clinical medicine

    Cite this